Drugs / Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection
Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06393166 Background | May 2023 → May 2025 | exocrine pancreatic carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06393166 ↗ |
| Route | Intravenous | “LV: 400 mg/m2 ,ivgtt over 2h” NCT06393166 ↗ |